Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression by Rosell, Rafael et al.
Customized Treatment in Non-Small-Cell Lung Cancer
Based on EGFR Mutations and BRCA1 mRNA Expression
Rafael Rosell
1,2*, Laia Perez-Roca
1, Jose Javier Sanchez
3, Manuel Cobo
4, Teresa Moran
1, Imane Chaib
1,
Mariano Provencio
5, Manuel Domine
6, Maria Angeles Sala
7, Ulpiano Jimenez
8, Pilar Diz
9,
Isidoro Barneto
10, Jose Antonio Macias
11, Ramon de las Pen ˜as
12, Silvia Catot
13, Dolores Isla
14,
Jose Miguel Sanchez
15¤, Rafael Ibeas
16, Guillermo Lopez-Vivanco
17, Juana Oramas
18, Pedro Mendez
1,
Noemi Reguart
19, Remei Blanco
20, Miquel Taron
1,2
1Catalan Institute of Oncology, Badalona, Spain, 2Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Spain, 3Autonomous University of Madrid, Madrid, Spain,
4Hospital Clinico Carlos Haya, Malaga, Spain, 5Hospital Puerta de Hierro, Madrid, Spain, 6Fundacio ´n Jimenez Diaz, Madrid, Spain, 7Hospital Basurto, Bilbao, Spain,
8Hospital de la Princesa, Madrid, Spain, 9Complejo Hospitalario de Leon, Leon, Spain, 10Hospital Reina Sofia, Cordoba, Spain, 11Hospital Morales Meseguer, Murcia,
Spain, 12Hospital Provincial de Castellon, Castellon, Spain, 13Althaia, Manresa, Spain, 14Hospital Clinico Lozano Blesa, Zaragoza, Spain, 15Hospital de Alcorcon, Madrid,
Spain, 16Hospital Municipal de Badalona, Badalona, Spain, 17Hospital de Cruces, Barakaldo, Spain, 18Hospital Universitario de Canarias, Tenerife, Spain, 19Hospital
Clinic, Barcelona, Spain, 20Hospital de Terrassa, Barcelona, Spain
Abstract
Background: Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC)
treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations,
with improved outcome to gefitinib and erlotinib. Experimental evidence suggests that BRCA1 overexpression enhances
sensitivity to docetaxel and resistance to cisplatin. RAP80 and Abraxas are interacting proteins that form complexes with
BRCA1 and could modulate the effect of BRCA1. In order to further examine the effect of EGFR mutations and BRCA1 mRNA
levels on outcome in advanced NSCLC, we performed a prospective non-randomized phase II clinical trial, testing the
hypothesis that customized therapy would confer improved outcome over non-customized therapy. In an exploratory
analysis, we also examined the effect of RAP80 and Abraxas mRNA levels.
Methodology/Principal Findings: We treated 123 metastatic non-squamous cell lung carcinoma patients using a
customized approach. RNA and DNA were isolated from microdissected specimens from paraffin-embedded tumor tissue.
Patients with EGFR mutations received erlotinib, and those without EGFR mutations received chemotherapy with or without
cisplatin based on their BRCA1 mRNA levels: low, cisplatin plus gemcitabine; intermediate, cisplatin plus docetaxel; high,
docetaxel alone. An exploratory analysis examined RAP80 and Abraxas expression. Median survival exceeded 28 months for
12 patients with EGFR mutations, and was 11 months for 38 patients with low BRCA1, 9 months for 40 patients with
intermediate BRCA1, and 11 months for 33 patients with high BRCA1. Two-year survival was 73.3%, 41.2%, 15.6% and 0%,
respectively. Median survival was influenced by RAP80 expression in the three BRCA1 groups. For example, for patients with
both low BRCA1 and low RAP80, median survival exceeded 26 months. RAP80 was a significant factor for survival in patients
treated according to BRCA1 levels (hazard ratio, 1.3 [95% CI, 1–1.7]; P=0.05).
Conclusions/Significance: Chemotherapy customized according to BRCA1 expression levels is associated with excellent
median and 2-year survival for some subsets of NSCLC patients , and RAP80 could play a crucial modulating effect on this
model of customized chemotherapy.
Trial Registration: ClinicalTrials.gov NCT00883480
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Introduction
The median survival of patients with advanced or metastatic
non-small-cell lung cancer (NSCLC) is only 10–11 months with
either standard cisplatin-based chemotherapy [1,2] or customized
cisplatin-based chemotherapy based on excision repair cross-
complementing 1 (ERCC1) mRNA expression,[3] and the two-
year survival rate is only 14–21%.[1,2,3]
The two proto-oncogenes currently known to be more
commonly mutated in lung adenocarcinoma are K-RAS and
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5133EGFR[4]. Lung cancers caused by activating mutations in the
epidermal growth factor receptor (EGFR) – mainly either deletion
at exon 19 or L858R mutation at exon 21 – respond to small
molecule tyrosine kinase inhibitors (gefitinib and erlotinib),[5,6,7]
with a recently reported median survival to gefitinib of
17.5 months.[8] Response rate was 90% in our retrospective trial
examining EGFR mutations in patients treated with gefitinib,[9]
and pooled data of prospective trials of gefitinib in patients with
EGFR mutations showed a response rate of 80%.[10] However,
no EGFR mutations were found in 454 patients with squamous
cell carcinoma of the lung.[11]
A growing body of evidence indicates that the breast cancer
susceptibility gene 1 (BRCA1) confers sensitivity to apoptosis
induced by antimicrotubule drugs (paclitaxel and vincristine) but
induces resistance to DNA-damaging agents (cisplatin and
etoposide) and radiotherapy.[12,13,14,15] These pre-clinical
findings are supported by a variety of experimental models in
breast and ovarian cancer cells: inducible expression of BRCA1
enhanced paclitaxel sensitivity;[16] a short interfering RNA-
mediated inactivation of endogenous BRCA1 led to paclitaxel and
docetaxel resistance;[17,18,19] and reconstitution of BRCA1-
deficient cells with wild-type BRCA1 enhanced sensitivity to
paclitaxel and vinorelbine.[17] This differential modulating effect
of BRCA1 mRNA expression was also observed in tumor cells
isolated from malignant effusions of NSCLC and gastric cancer
patients, where BRCA1 mRNA levels correlated negatively with
cisplatin sensitivity and positively with docetaxel sensitivity.[20]
Two retrospective studies – in NSCLC [21] and ovarian
cancer[19] patients – found that low or intermediate BRCA1
mRNA levels correlated with a significantly longer survival
following platinum-based chemotherapy,[19,21] while survival in
patients with higher BRCA1 expression increased following
taxane-based chemotherapy.[19]
BRCA1 is recruited to the sites of DNA breaks, playing a central
role in DNA repair and in cell-cycle checkpoint control. Binding of
the mediator of DNA damage checkpoint 1 (MDC1) protein to the
phosphorylated tail of histone H2AX facilitates the formation of
BRCA1 nuclear foci at double-strand breaks.[22] The receptor-
associated protein 80 (RAP80) acts upstream of BRCA1 and is
required for the accumulation of BRCA1 to sites of DNA
breaks.[23,24,25] Abraxas recruits RAP80 to form a complex
with BRCA1. Both Abraxas and RAP80 are required for DNA
damage repair, and cells depleted of Abraxas or RAP80 exhibit
hypersensitivity to irradiation.[23]
In order to examine whether customizing treatment could
improve outcome in advanced NSCLC patients, we have
performed a prospective non-randomized phase II trial of
customized treatment based on EGFR mutation status and BRCA1
mRNA expression levels. We opted to limit enrollment to non-
squamous cell carcinoma in order to maximize the opportunity to
administer erlotinib in patients with EGFR mutations. Patients with
either the exon 19 deletion or the L858R mutation received
erlotinib, while those with wild-type EGFR received chemotherapy
based on BRCA1 levels: those with low levels received cisplatin plus
gemcitabine; those with intermediate levels received cisplatin plus
docetaxel; and those withhighlevels received docetaxel alone. In an
exploratory analysis, we also examined the effect of RAP80 and
Abraxas mRNA levels in these patients.
Results
Patients
Between March 2005 and July 2007, a total of 123 patients from
25 centers were enrolled in the study (Figure 1). Thirty-five
patients were excluded: 3 patients had no tumor cells in the biopsy;
5 patients had less than 50 tumor cells in the biopsy, making it
impossible to assure correct results; 19 patients were wild-type
EGFR but with insufficient tumor sample after EGFR assessment
for BRCA1 expression analysis; 2 patients refused to participate;
and 6 patients were withdrawn by their physician due to clinical
factors unrelated to the study. For all 123 patients, RNA isolation
and PCR amplification were successful. On average, results of
genetic analyses were available in 8 days (range, 6–11 days). The
median number of cycles of chemotherapy administered in the
BRCA1 groups was 5 (range, 1.8). Median follow-up was
8 months (range, 1–28 months). Twelve patients had EGFR
mutations and were assigned to receive erlotinib (EGFR group).
Of the 111 patients with wild-type EGFR, 38 were in the lowest
tercile of BRCA1 expression and were assigned to receive cisplatin
plus gemcitabine (low BRCA1 group), 40 were in the intermediate
tercile and were assigned to receive cisplatin plus docetaxel
(intermediate BRCA1 group), and 33 were in the highest tercile
and were assigned to receive docetaxel alone (high BRCA1 group)
(Figure 1).
The clinical characteristics of the four groups are shown in
Table 1 and Table S1. Median age for all patients was 60 years.
Proportionally more females than males were in the lowest tercile
of BRCA1 expression. EGFR mutations were more frequently
observed in never-smokers (P=0.03) and females (P=0.0001).
Fifty-five percent of patients had a performance status of 1, and
83% had stage IV disease. Seventeen percent of patients had brain
metastases. Patients with EGFR mutations had a median of two
metastatic sites, compared to one site in patients with wild-type
EGFR (Table S2).
The overall response rate was 90% for the EGFR group, 25%
for the low BRCA1 group, 45.7% for the intermediate BRCA1
group, and 41.9% for the high BRCA1 group (Table 2). In the
intent-to-treat analysis, the response rate was 75% for the EGFR
group, 21.1% for the low BRCA1 group, 40% for the intermediate
BRCA1 group, and 39.4% for the high BRCA1 group (Table 2).
Median survival was not reached but exceeded 28 months for
the EGFR group, compared to 10 months (95% CI, 8.5 to 15–5)
for patients in all three BRCA1 groups. Two-year survival for
patients in the EGFR group was 73.3% and for all patients in the
BRCA1 groups it was 26.7%. For patients in the low BRCA1
group, median survival was 11 months (95% CI, 1.1 to 20.9) and
2-year survival was 41.2%. For those in the intermediate BRCA1
group, median survival was 9 months (95% CI, 5.4 to 12.6) and 2-
year survival was 15.6%. For patients in the high BRCA1 group,
median survival was 11 months (95% CI, 8.2 to 13.8) and 2-year
survival was 0% (Table 2, Figure 2).
Median time to progression was 13 months (95% CI, 7.7 to
18.3) in the EGFR group, compared to 6 months (95% CI, 4.7 to
7.2) for patients in all three BRCA1 groups. For patients in the low
and intermediate BRCA1 groups, time to progression was
5 months (95% CI, 2.7 to 7.3). For patients in the high BRCA1
group, time to progression was 8 months (95% CI, 5.1 to 10.9)
(Table 2, Figure S1).
RAP80 and Abraxas mRNA transcripts
Based on the results of experimental models[23,24,25], an
exploratory analysis of the relation between BRCA1, RAP 80 and
Abraxas mRNA expression was performed in 86 of 111 patients
without EGFR mutations for whom sufficient tumor tissue was
available. Patient characteristics for these 86 patients were similar
to those of all 111 patients; significantly more females than males
had low BRCA1 expression (P=0.009). Response was significantly
higher in patients with intermediate and high BRCA1 levels
EGFR & BRCA1 mRNA in NSCLC
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BRCA1 and RAP 80 levels (r=0.27; P=0.02) and between RAP
80 and Abraxas levels (r=0.41; P,0.001) but not between
BRCA1 and Abraxas levels (r=0.10; P=0.39).
Median survival was influenced by RAP 80 levels. In patients
with low BRCA1 levels, median survival was not reached in
patients with low RAP 80 levels, while it was 8 months for patients
with intermediate RAP 80 and 7 months for those with high RAP
80 (Table 3, Figure 3). In patients with intermediate BRCA1
levels, median survival was 5 months in patients with low RAP 80
levels, while it was 13 months for patients with intermediate RAP
80 levels and 16 months for those with high RAP 80 levels. In
patients with high BRCA1 levels, median survival was 6 months in
patients with low RAP 80 levels, 12 months in patients with
Figure 1. Consolidated Standards of Reporting Trials diagram showing flow of patients through study. Between March 2005 and July
2007, a total of 123 patients from 25 centers were enrolled in the study. Reasons for patient withdrawal: 3 patients had no tumor cells in the biopsy; 5
patients had less than 50 tumor cells in the biopsy, making it impossible to assure correct results; 19 patients were wild-type EGFR but with
insufficient tumor sample after EGFR assessment for BRCA1 expression analysis; 2 patients refused to participate; and 6 patients were withdrawn by
their physician due to clinical factors unrelated to the study. The two patients in the EGFR group who were not evaluable for response died within a
month of entering the study; the 13 patients in the BRCA1 who were not evaluable for response received .3 cycles of treatment.
doi:10.1371/journal.pone.0005133.g001
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All patients EGFR Group BRCA1 Groups
Low Intermediate High
N=123 N=12 N=38 N=40 N=33
N( % ) N( % ) N( % ) N( % ) N( % )
Age Median(range) 60 (36–78) 60 (42–70) 60 (36–77) 58 (43–78) 60 (42–75)
Gender Female 38 (30.9) 9 (75) 15 (39.5) 11 (27.5) 3 (9.1)
Male 85 (69.1) 3 (25) 23 (60.5) 29 (72.5) 30 (90.9)
Smoker Current 40 (32.5) 1 (8.3) 7 (18.4) 18 (45) 14 (42.4)
Never 26 (21.1) 7 (58.3) 8 (21.1) 8 (20) 3 (9.1)
Former 57 (46.4) 4 (33.4) 23 (60.5) 14 (35) 16 (48.5)
Race Caucasian 122 (99.2) 12 (100) 38 (100) 39 (97.5) 33 (100)
Other 1 (0.8) 0 (0) 0 (0) 1 (2.5) 0 (0)
ECOG PS 0 44 (35.8) 6 (50) 15 (41.7) 12 (30.7) 11 (33.3)
1 68 (55.3) 5 (41.7) 20 (55.5) 23 (58.9) 20 (60.6)
2 8 (6.5) 1 (8.3) 1 (2.8) 4 (10.4) 2 (6.1)
NR 3 (2.4) 0 2 1 0
Histology Adeno 83 (67.5) 8 (66.7) 27 (71.1) 27 (67.5) 21 (63.)
BAC 10 (8.1) 3 (25) 5 (13.2) 2 (5) 0 (0)
LCC 14 (11.4) 1 (8.3) 2 (5.3) 5 (12.5) 6 (18.2)
NOS 16 (13) 0 4 (10.5) 6 (15) 6 (18.2)
Stage III 21 (17.1) 3 (25) 10 (26.3) 5 (12.5) 3 (9.1)
IV 102 (82.9) 9 (75) 28 (73.7) 35 (87.5) 30 (90.9)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NR, not recorded; adeno, adenocarcinoma; BAC, bronchioloalveolar carcinoma; LCC, large cell
carcinoma; NOS, non-specified;
doi:10.1371/journal.pone.0005133.t001
Table 2. Outcomes according to treatment groups
All Patients EGFR Group BRCA1 Groups
Low Intermediate High
(n=123) (n=12) (n=38) (n=40) (n=33)
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Outcome CR 3.3 16.7 0 2.5 3
PR 34.1 58.3 21.1 37.5 36.4
SD 30.1 8.3 47.4 17.5 33.3
PD 20.3 0 15.8 30 21.2
ND 12.2 16.7 15.8 12.5 6.1
ORR 43.6 90 25 45.7 41.9
Intent to treat 37.4 75 21.1 40 39.4
Survival MS, mo 12 mo 8.5–15.5 NR (.28 mo) - 11 mo 1–20.9 9 mo 5.4–12.6 11 mo 8.2–13.8
1-yr 49.2 39.5–58.8 91.7 57.2–100 47.8 30.9–64.6 41.1 23.6–58.4 42.4 23.5–61.1
2-yr 31.5 21.1–41.9 73.3 17.6–100 41.2 24.3–58 15.6 0–32.2 0
28 mo 24.5 12.7–36.3 73.3 17.6–100 35.3 17.4–53.1 0 - 0
TTP 6 mo 4.2–7.7 13 mo 7.7–18.3 5 mo 2.7–7.3 5 mo 2.7–7.3 8 mo 5.1–10.9
ORR, overall response rate; TTP, time to progression; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ND, not determined; MS,
median survival
doi:10.1371/journal.pone.0005133.t002
EGFR & BRCA1 mRNA in NSCLC
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RAP 80 levels (Table 3).
In patients with low BRCA1 levels, time to progression was
14 months in patients with low RAP 80 levels, while it was
4 months for patients with intermediate RAP80 levels and
6 months for those with high RAP 80 levels (Table 4, Figure
S2). In patients with intermediate BRCA1 levels, time to
progression was 4 months in patients with low RAP 80 levels,
while it was 9 months for patients with intermediate RAP 80 levels
and 6 months for those with high RAP 80 levels. In patients with
high BRCA1 levels, time to progression was 2 months in patients
with low RAP 80 levels, 10 months in patients with intermediate
RAP 80 levels, and 4 months for those with high RAP 80 levels
(Table 4).
Similar results were obtained when median survival and time to
progression were compared according to Abraxas mRNA
expression levels (Tables S4 and S5). An exploratory multivariate
analysis in the 86 patients, with the use of a Cox proportional-
hazards model, identified ECOG performance status and RAP 80
as significant variables for survival (hazard ratios: performance
status 1, 2.72; P=0.005; RAP 80, 1.3; P=0.05) (Table S6).
Survival was not influenced by other clinical characteristics, types
Figure 2. Median survival according to treatment group. Median survival was not reached for 12 patients in the EGFR group, 11 months for 38
patients in the low BRCA1 group, 9 months for 40 patients in the intermediate BRCA1 group, and 11 months for 33 patients in the high BRCA1 group
(P=0.01) (see Table 2).
doi:10.1371/journal.pone.0005133.g002
Table 3. Median survival according to levels of BRCA1 and RAP80
RAP 80 LEVELS
#0.79 0.79–1.41 .1.41
BRCA1 Levels N months (95% CI) N months (95% CI) N months (95% CI) P
Low 11 NR (-) 9 8 (1.6–14.4) 5 7 (4.5–9.5) 0.10
Intermediate 11 5 (3.4–6.6) 7 13 (10–15.9) 16 16 (5.5–26.5) 0.15
High 5 6 (1.8–10.1) 9 12 (9.3–14.6) 12 11 (8.2–13.8) 0.17
CI, confidence interval; NR, not reached
doi:10.1371/journal.pone.0005133.t003
EGFR & BRCA1 mRNA in NSCLC
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levels. The Cox model for time to progression also showed that
only performance status and RAP 80 were significant variables
(Table S7).
Discussion
Mutations in the EGFR tyrosine kinase domain induce lung
adenocarcinoma in mice[26] and a favorable response to first- and
second-line gefitinib and erlotinib in advanced NSCLC.[7,8] In
the present study, median survival exceeded 28 months in 12
patients with EGFR mutations treated with erlotinib, with a
median time to progression of 13 months and a two-year survival
of 73.3%; these results are similar to the findings of a meta-analysis
of prospective trials with gefitinib in patients with EGFR
mutations.[10] Median survival was 11 months in patients with
the lowest BRCA1 expression, treated with cisplatin plus
gemcitabine, and two-year survival was 41.2%, which compares
favorably with the median and two-year survival attained with
gemcitabine plus cisplatin or pemetrexed plus cisplatin
(10.3 months and 22%) in a recent randomized trial.[2] In
patients with the highest BRCA1 expression, treated with
Figure 3. Median survival for patients with low BRCA1 levels, treated with cisplatin plus gemcitabine, according to RAP 80 mRNA
expression. Median survival was not reached for 11 patients with low RAP 80 levels, 8 months for 9 patients with intermediate RAP 80 levels, and
7 months for 5 patients with high RAP 80 levels (P=0.006).
doi:10.1371/journal.pone.0005133.g003
Table 4. Time to progression according to levels of BRCA1 and RAP 80
RAP 80 LEVELS
#0.79 0.79–1.41 .1.41
BRCA1 Levels N months (95% CI) N months (95% CI) N months (95% CI) P*
Low 11 14 (5–22.9) 9 4 (2.8–5.1) 5 6 (-) 0.08
Intermediate 11 4 (3.1–4.9) 7 9 (2.5–15.5) 9 6 (3.1–8.9) 0.42
High 5 2 (0–4.1) 9 10 (7.3–12.6) 12 4 (1.7–6.3) 0.006
CI, confidence interval
*All p-values were corrected using the Bonferroni method.
doi:10.1371/journal.pone.0005133.t004
EGFR & BRCA1 mRNA in NSCLC
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obtained in a large phase III trial in patients treated with docetaxel
plus cisplatin.[1] However, in our study, no patient was alive at
two years, while in the phase III trial, two-year survival was
21%.[1] Intriguingly, 11 patients with the lowest expression of
both BRCA1 and RAP 80 had an outcome similar to that attained
by patients with EGFR mutations treated with erlotinib: median
survival was not reached and time to progression was 14 months
(Table 3, Figure 3).Chemotherapy response is solidly based on the
fact that DNA repair genes require a series of molecular recognition
steps that enable DNA damage response proteins to localize at and
near DNA lesions. Binding of the mediator of DNA damage
checkpoint 1 (MDC1) protein to the phosphorylated tail of histone
H2AX (cH2AX) facilitates the formation of BRCA1 nuclear foci at
double-strand breaks induced by irradiation or chemotherapy. By
dimerizing with BRCA1-associated RING domain (BARD1)
protein through the RING domain, BRCA1 forms an E3 ubiquitin
ligase. Recently, ithasbeen shown that RAP80 targets theBRCA1-
BARD1 E3 ligase to MDC1-cH2AX-dependent lysine 63-linked
ubiquitin proteins at double-strand breaks (reviewed in Wang &
Elledge[27]). Three studies showed that the abrogation of RAP 80
reduced the formation of BRCA1-induced foci to 28%,[23] 2%[24]
and 0%.[25] Moreover, Abraxas and RAP 80 foci formation is
BRCA1-independent.[23] We therefore hypothesized that if RAP
80 was elevated, it could cause resistance to cisplatin-based
chemotherapy even in the presence of low BRCA1 levels. The
exploratory assessment of RAP 80 in the present study confirms its
modulating effect on the BRCA1 customized model. For example,
median survival in patients with the lowest BRCA1 expression
decreased as RAP 80 expression increased: 8 months with
intermediate RAP 80 levels and 7 months with high RAP 80 levels
(Table 3).Overexpression of BRCA1 confers sensitivity to docetaxel
and paclitaxel;[12,17,19,20] patients with the highest levels of
BRCA1, treated with docetaxel, had a median survival of 11–
12 months when RAP80 expression was also high but only
6 months when RAP 80 expression was low (Table 3). Patients
with intermediate BRCA1 levels, treated with cisplatin plus
docetaxel, had an overall median survival of 9 months, which
increased to 13–16 months when RAP 80 levels were intermediate
or high (Table 3). These results can be explained by pre-clinical
findings that RAP 80 is able to translocate to irradiation-induced
foci in HCC1937 cells which express a truncated BRCA1 that is
unable to migrate to nuclear foci.[28] This indicates that RAP 80
could replace the BRCA1 DNA repair function in cells lacking
BRCA1. Thus, although different platinum doublets show the
same[29] – or slightly different[2] – survival overall, differences
could be found when customizing chemotherapy based on a model
of BRCA1 and RAP 80.
In the present study, no correlation was found between BRCA1
and Abraxas mRNA expression. However, there was an indication
that expression levels of Abraxas modulate the effect of BRCA1.
For example, patients with the lowest BRCA1 expression, treated
with cisplatin plus gemcitabine, attained a median survival of
18 months and time to progression of 11 months when Abraxas
levels were low (Table S4).
In addition to the potential predictive role of BRCA1, BRCA1
overexpression confers aggressive behavior in transgenic models of
small cell and squamous cell lung carcinomas, as well as in a subset
of lung adenocarcinomas harboring the intrinsic T/t-antigen
cancer signature.[30] Poor prognosis has also been associated with
BRCA1 overexpression in early NSCLC.[31] In the present study,
two-year survival was 41% in patients with the lowest levels of
BRCA1, 16% in those with intermediate levels and 0% in those
with the highest levels.
The mechanisms of BRCA1 overexpression or downregulation
in NSCLC remain to be clarified. However, it has recently been
shown that DNA breaks swiftly activate heterochromatin protein
1-b (HP1-b), which promotes histone H2AX phosphorylation,
initiating the BRCA1 signaling assembly for DNA repair.[32]
Intriguingly, casein kinase 2 promotes the mobilization of HP1-b
and is associated with poor prognosis in NSCLC.[33] While
BRCA1 methylation is observed in ductal breast cancer, it is only
found in 4% of NSCLCs.[34] Low BRCA1 expression in tumors
may be due to the loss of histone methyltransferases, which leads
to decreased chromatin H3 methylation in lysine 9, with the
consequent downregulation of HP1-b.[35]
In this phase II, non-randomized study, the genetic factor and
treatment difference are entirely co-existing, and caution should be
exercised when interpreting the results. However, the exploratory
analysis indicates that there is some evidence for tailoring
chemotherapy based on BRCA1 and RAP 80 levels. Moreover,
in a recent study of 96 stage IV NSCLC patients treated with
docetaxel plus gemcitabine, we observed that as BRCA1 mRNA
levels increased, the probability of response increased and the risk
of progression decreased. For patients with the highest BRCA1
levels, the response rate was 58.6%, compared to 13.8% for those
with intermediate levels and 27.6% for those with the lowest
levels.[36] Based on these findings and those of the present study,
the Spanish Lung Cancer Group is now modifying the protocol for
a planned international phase III trial in advanced NSCLC to
include customization based on RAP 80 as well as BRCA1 mRNA
expression. Patients in the control arm will receive cisplatin plus
docetaxel and those in the experimental arm will receive
chemotherapy based on RAP 80 and BRCA1 mRNA levels: low
RAP 80 levels (regardless of BRCA1 levels), cisplatin plus
gemcitabine; intermediate or high RAP 80 and low or interme-
diate BRCA1, cisplatin plus docetaxel; intermediate or high RAP
80 and high BRCA1, docetaxel alone.
Materials and Methods
The protocol for this trial is available as supporting information;
see Protocol S1 and Protocol S2.
Ethics statement
The protocol was approved by each center’s institutional ethics
review board, and all patients provided written informed consent
before enrollment.
Patients
We recruited patients to this phase II prospective multicenter
trial based on screening of EGFR mutations followed by BRCA1
mRNA expression analysis in paraffin-embedded tumor tissue.
Clinical eligibility included stage IIIB with pleural effusion or stage
IV NSCLC, measurable disease by Response Evaluation Criteria
in Solid Tumors (RECIST), performance status 0–2 by Eastern
Cooperative Oncology Group (ECOG) criteria, adequate hema-
tologic, renal and hepatic function. Brain metastases were allowed.
Patients with squamous cell tumors, prior systemic therapy for
advanced NSCLC, or other clinically significant cancers within
five years were not eligible.
Patients with EGFR mutations – either the exon 19 deletion or
the L858R mutation – received 150 mg of daily oral erlotinib
continuously until progression or intolerable adverse effects. Each
cycle was 28 days. Patients with wild-type EGFR received
customized chemotherapy based on BRCA1 mRNA levels.
Patients in the lowest tercile of BRCA1 expression received
cisplatin 75 mg/m
2 on day 1 plus gemcitabine 1250 mg/m
2 on
EGFR & BRCA1 mRNA in NSCLC
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75 mg/m
2 on day 1 plus docetaxel 75 mg/m
2 on day 1. Patients
in the highest tercile received docetaxel 75 mg/m
2 on day 1. All
chemotherapy was repeated every three weeks for a maximum of
six cycles unless there was earlier evidence of disease progression
or intolerable adverse effects.
Baseline assessment included a medical history, physical
examination and tumor measurements of palpable lesions as well
as lesions assessed by computed tomography scans. The baseline
assessment method was repeated every other cycle, and then every
six weeks until disease progression.
Molecular analyses
Tumor tissue collection and laser capture
microdissection. BRCA1, RAP80 and Abraxas gene
expression and EGFR mutations were analyzed in RNA and
DNA isolated from paraffin-embedded tumor tissues. For each
tumor sample a haematoxylin/eosin stained slice was analyzed by
our pathologist to select the tumor area. Two 5-micron slices were
mounted on special slides (Pem-Membrane slides, Palm,
Oberlensheim, Germany) for laser capture microdissection
(CAPmover Microdissector, Carl Zeiss Microimaging, Barcelona,
Spain) to ensure a minimum of 90% of tumor cells. One slide was
used for RNA isolation and the second was used for DNA
isolation.
Gene expression analysis. Gene expression analysis was
performed in RNA isolated from the tumor tissue specimens.
cDNA was synthesized using M-MLV retrotranscriptase enzyme.
Template cDNA was added to Taqman Universal Master Mix
(AB; Applied Biosystems, Foster City, CA, USA) with specific
primers and probe for each gene (Table S8). The primer and
probe sets were designed using Primer Express 2.0 Software (AB)
and the RefSeq sequences (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=gene). Quantification of gene expression was
performed using the ABI Prism 7900HT Sequence Detection
System (AB).
EGFR mutation analysis. For isolation of DNA from
microdissected tissue, the material was incubated with proteinase
K and DNA was extracted with phenol-chloroform and ethanol
precipitation. Primers for PCR amplification in nested reactions
for exons 19 and 21 of EGFR are shown in the supporting
information. Mutations were analyzed using two methods: DNA
sequencing and length analysis of fluorescently labeled PCR
products for EGFR deletions in exon 19, and sequencing and 59
nuclease activity assay (TaqMan) for EGFR mutation in exon 21
(L858R).
(For further details on the molecular analyses, see Text S1).
Statistical analysis
Patients were divided into groups based on terciles of BRCA1
expression since this division is less susceptible to bias in multiple
comparisons. Cut-off points for the BRCA1 terciles were obtained
from the Spanish Lung Cancer Group data base, which includes
clinical and genetic characteristics of more than 600 Spanish lung
cancer patients. Responses were recorded according to the
RECIST criteria. Median time to progression and overall survival
were calculated from the start of treatment to the first documented
disease progression or death, respectively.
In order to compare quantitative variables among patients in
each of the treatment groups, to explore associations between
variables within each group, and to study the potential association
between baseline characteristics and response, we used parametric
tests (student’s t-test or ANOVA) or their equivalent non-
parametric tests (U Mann-Whitney, Kruskall Wallis) when
normality did not hold. The normality of continuous variables
was checked with the Kolmogorov-Smirnov test. In order to
compare categorical variables and response percentages with their
95% CIs among treatment groups, we used either the two-sided
Fisher’s exact test or the Chi-square test.
The association of risk factors with time-to-event endpoints was
analyzed with the two-sided logrank test, and the Kaplan-Meier
method was used to plot the corresponding time-to-progression
and survival curves. A univariate Cox regression analysis, with
hazard ratios and their 95% CIs was used to assess the association
between each potential prognostic factor and survival and time to
progression. These factors were then included in a multivariate
Cox proportional hazards regression model to evaluate the
independent significance of each variable on survival and time
to progression. The likelihood ratio test was used to assess the
goodness of fit, and the Wald’s test was used to assess the
coefficient significance. For potential multiple comparisons, the p-
values were corrected with the Bonferroni correction.
Eighty-six of the 111 patients without EGFR mutations for
whom sufficient tumor tissue was available were included in an
exploratory sub-analysis of the relation between BRCA1, RAP80
and Abraxas expression. Spearman’s rank test was used to
evaluate the correlation between BRCA1, RAP80 and ABRAXAS
mRNA expression.
All statistical calculations were performed with the SPSS
software statistical package, version 15.0 (SPSS, Inc., Chicago,
IL, USA) and S-PLUS 6.1. Two-sided p-values of less than 0.05
were considered significant.
Supporting Information
Text S1 Supplemental text
Found at: doi:10.1371/journal.pone.0005133.s001 (0.04 MB
DOC)
Table S1 Clinicopathological characteristics, gene expression
levels, EGFR mutation status, and outcomes for all patients
Found at: doi:10.1371/journal.pone.0005133.s002 (0.07 MB
XLS)
Table S2 Types of metastases
Found at: doi:10.1371/journal.pone.0005133.s003 (0.05 MB
DOC)
Table S3 Characteristics of 86 patients in whom RAP 80 and
Abraxas were analyzed
Found at: doi:10.1371/journal.pone.0005133.s004 (0.07 MB
DOC)
Table S4 Median survival according to levels of BRCA1 and
Abraxas
Found at: doi:10.1371/journal.pone.0005133.s005 (0.03 MB
DOC)
Table S5 Time to progression according to levels of BRCA1 and
Abraxas
Found at: doi:10.1371/journal.pone.0005133.s006 (0.03 MB
DOC)
Table S6 Multivariable COX model for survival with BRCA1
and RAP 80 as continuous variables
Found at: doi:10.1371/journal.pone.0005133.s007 (0.03 MB
DOC)
Table S7 Multivariable COX model for time to progression
with BRCA1 and RAP 80 as continuous variables
Found at: doi:10.1371/journal.pone.0005133.s008 (0.03 MB
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Figure S1 Time to progression according to treatment group.
Time to progression was 13 months in the EGFR group, 5 months
in the low and intermediate BRCA1 groups, and 8 months in the
high BRCA1 group (see Table 2).
Found at: doi:10.1371/journal.pone.0005133.s010 (8.92 MB TIF)
Figure S2 Time to progression for patients in the low BRCA1
group according to RAP 80 expression levels. Time to progression
was 14 months for patients with low RAP 80 levels, 4 months for
those with intermediate RAP 80 levels, and 6 months for those
with high RAP 80 levels (see Table 4).
Found at: doi:10.1371/journal.pone.0005133.s011 (10.31 MB
TIF)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0005133.s012 (1.12 MB
PDF)
Protocol S2 English summary of protocol
Found at: doi:10.1371/journal.pone.0005133.s013 (0.21 MB PDF)
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